|Day's Range||0.81 - 0.83|
|52 Week Range||0.26 - 1.51|
|PE Ratio (TTM)||-1.12|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investors in Protalix BioTherapeutics, Inc. (PLX) need to pay close attention to the stock based on moves in the options market lately.
Categories: Yahoo FinanceGet free summary analysis Protalix Biotherapeutics, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Protalix Biotherapeutics, Inc. – Amicus Therapeutics, Inc., Pfizer Inc., Neurocrine Biosciences, Inc. and Aviragen Therapeutics Inc (FOLD-US, PFE-US, NBIX-US and AVIR-US) that have also reported for this period. ... Read more (Read more...)
Q1 2017 Protalix Biotherapeutics Inc Earnings Call